Compare GDYN & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDYN | TECX |
|---|---|---|
| Founded | 2006 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 618.9M |
| IPO Year | 2018 | 2018 |
| Metric | GDYN | TECX |
|---|---|---|
| Price | $7.67 | $20.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 10 |
| Target Price | $9.40 | ★ $71.00 |
| AVG Volume (30 Days) | ★ 755.3K | 232.9K |
| Earning Date | 10-29-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 120.00 | 40.70 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $111,283,000.00 | N/A |
| Revenue This Year | $6.37 | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | $389.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.11 | $15.60 |
| 52 Week High | $10.21 | $39.53 |
| Indicator | GDYN | TECX |
|---|---|---|
| Relative Strength Index (RSI) | 46.40 | 27.01 |
| Support Level | $7.56 | $20.52 |
| Resistance Level | $8.22 | $30.80 |
| Average True Range (ATR) | 0.27 | 1.23 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 16.93 | 12.66 |
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. The company focuses on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.